Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB154 + Docetaxel + Zimberelimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB154 | AB-154|AB 154|Domvanalimab | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 | AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124). | |
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05676931 | Phase II | AB680 + Zimberelimab AB154 + Zimberelimab AB154 + AB680 + Zimberelimab AB680 + Docetaxel + Zimberelimab AB154 + Docetaxel + Zimberelimab | Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | AUS | 3 |